Human cell chimerism in the spleen of nonirradiated adult NSG and NSG-Tg(hu-mSCF) mice 12 weeks after engraftment of human HSCs
| Human cell subset . | NSG-Tg(hu-mSCF), 0 cGy (N = 6) . | NSG, 0 cGy (N = 6) . | ||
|---|---|---|---|---|
| % . | No, × 106 . | % . | No, × 106 . | |
| Total human leukocytes: CD45+ | 65.9 ± 29.7 | 11.8 ± 12.1 | 74.4 ± 10.6 | 4.0 ± 2.6 |
| Percentage of human CD45+ cells | ||||
| CD3+ T cells | 0.2 ± 0.4 | 0.2 ± 0.2 | ||
| CD20+ B cells | 53.0 ± 9.1 | 54.8 ± 11.0 | ||
| Myeloid/granulocytic | ||||
| CD33+ | 5.3 ± 4.1 | 2.0 ± 1.1 | ||
| CD14+ | 0.2 ± 0.2 | 0.1 ± 0.03 | ||
| Dendritic cell subsets | ||||
| CD11c+ | 1.3 ± 1.1 | 0.5 ± 0.2 | ||
| CD123+ | 3.6 ± 2.1 | 1.7 ± 0.6 | ||
| Human cell subset . | NSG-Tg(hu-mSCF), 0 cGy (N = 6) . | NSG, 0 cGy (N = 6) . | ||
|---|---|---|---|---|
| % . | No, × 106 . | % . | No, × 106 . | |
| Total human leukocytes: CD45+ | 65.9 ± 29.7 | 11.8 ± 12.1 | 74.4 ± 10.6 | 4.0 ± 2.6 |
| Percentage of human CD45+ cells | ||||
| CD3+ T cells | 0.2 ± 0.4 | 0.2 ± 0.2 | ||
| CD20+ B cells | 53.0 ± 9.1 | 54.8 ± 11.0 | ||
| Myeloid/granulocytic | ||||
| CD33+ | 5.3 ± 4.1 | 2.0 ± 1.1 | ||
| CD14+ | 0.2 ± 0.2 | 0.1 ± 0.03 | ||
| Dendritic cell subsets | ||||
| CD11c+ | 1.3 ± 1.1 | 0.5 ± 0.2 | ||
| CD123+ | 3.6 ± 2.1 | 1.7 ± 0.6 | ||
Nonirradiated NSG and NSG-Tg(hu-mSCF) mice 6-10 weeks of age were engrafted with human HSCs as described in “Engraftment of mice with human HSCs.” Mice were analyzed by flow cytometry 12 weeks later for the percentage and number of human CD45+ and the percentage of human CD45+ cells that were positive for specific lineage markers in the spleen. Data are mean ± SD. No significant differences between groups were observed.